Full Press Release Details
InMed Pharmaceuticals
Appoints Mr. John Bathery to Board of Directors
Vancouver, British Columbia - October 16,
2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on
developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment
of Mr. John Bathery to its Board of Directors, effective immediately.
Mr. Bathery brings more than 30 years of experience
in the pharmaceutical industry, including over 15 years in corporate development and strategic partnerships. He currently serves as Head
of Global Business Development Operations & Externalization at Takeda Pharmaceuticals, where he has overseen pipeline and commercial
divestitures, global alliance management, and integration of corporate transactions. Over his career, he has led and closed transactions
with financial terms exceeding $60 billion across M&A, licensing, divestments, and collaborations.
Mr. Bathery's extensive background in evaluating
preclinical and early-stage assets, structuring value-creating partnerships, and leading cross-functional global initiatives will be highly
relevant as InMed advances both its INM-901 program for Alzheimer's disease and INM-089 program in Age-Related Macular Degeneration
("AMD") toward clinical readiness and explores potential partnerships.
Andrew Hull, Chairman of the Board of InMed, commented:
"We are delighted to welcome John to InMed's
Board. His extensive deal-making expertise and proven ability to structure partnerships at the preclinical stage will be instrumental
as we advance our development programs and pursue strategic collaborations. John's experience in global business development and
corporate development will be a strong asset as we position the Company for future growth."
Mr. John Bathery, commented:
"I am pleased to join InMed's Board
at this pivotal stage in the Company's growth. The consistent positive results seen with INM-901 across multiple parameters are
particularly encouraging and highlight the strength of InMed's research. I look forward to supporting the team as we advance InMed's
programs and explore strategic opportunities to maximize their potential."
InMed Pharmaceuticals is a pharmaceutical
company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's
pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information,
visit www.inmedpharma.com.
Vice President, Investor Relations
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects",
"anticipates", "believes", "intends", "potential", "possible", "would"
and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks
and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1. of the
Annual Report for the period ended June 30, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.